<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Office of Technology and Business Development</title>
	<atom:link href="http://www.otbd.org/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.otbd.org</link>
	<description>Bringing Technology to Life</description>
	<lastBuildDate>Fri, 24 May 2013 13:44:10 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.1</generator>
		<item>
		<title>Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles</title>
		<link>http://www.otbd.org/icahn-school-of-medicine-at-mount-sinai-grants-exclusive-license-to-cellular-dynamics-international-for-development-of-a-cellular-therapy-for-cardiac-muscles/</link>
		<comments>http://www.otbd.org/icahn-school-of-medicine-at-mount-sinai-grants-exclusive-license-to-cellular-dynamics-international-for-development-of-a-cellular-therapy-for-cardiac-muscles/#comments</comments>
		<pubDate>Fri, 24 May 2013 13:44:10 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Blue Mountain]]></category>

		<guid isPermaLink="false">http://www.otbd.org/?p=2162</guid>
		<description><![CDATA[May 24, 2013 - The Icahn School of Medicine at Mount Sinai has granted Cellular Dynamics International (CDI) exclusive license rights  to commercially develop cardiomyocyte progenitors for in vivo cell therapy and regenerative medicine applications. These cells are capable of further differentiation into the multiple cell types of the heart, including cardiomyocytes, endothelial cells, and vascular smooth muscle cells, [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/icahn-school-of-medicine-at-mount-sinai-grants-exclusive-license-to-cellular-dynamics-international-for-development-of-a-cellular-therapy-for-cardiac-muscles/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh To Collaborate On Clinical Studies For Mucopolysaccharidoses</title>
		<link>http://www.otbd.org/icahn-school-of-medicine-at-mount-sinai-and-bene-pharmachem-gmbh-to-collaborate-on-clinical-studies-for-mucopolysaccharidoses/</link>
		<comments>http://www.otbd.org/icahn-school-of-medicine-at-mount-sinai-and-bene-pharmachem-gmbh-to-collaborate-on-clinical-studies-for-mucopolysaccharidoses/#comments</comments>
		<pubDate>Wed, 15 May 2013 15:05:18 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>

		<guid isPermaLink="false">http://www.otbd.org/?p=2140</guid>
		<description><![CDATA[May 15, 2013 &#8211; The Icahn School of Medicine at Mount Sinai has signed an agreement with bene pharmaChem GmbH to collaborate to conduct clinical studies of pentosan polysulfate (PPS) in patients with mucopolysaccharidoses (MPS). The company, based in Germany, is the sole producer of pharmaceutical pentosan polysulfate. The announcement was made on Wednesday, May 15, which is International MPS [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/icahn-school-of-medicine-at-mount-sinai-and-bene-pharmachem-gmbh-to-collaborate-on-clinical-studies-for-mucopolysaccharidoses/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mount Sinai Invents Gene Signature to Identify Individuals with Cirrhosis at High-Risk for Liver Cancer</title>
		<link>http://www.otbd.org/mount-sinai-invents-gene-signature-to-identify-individuals-with-cirrhosis-at-high-risk-for-liver-cancer/</link>
		<comments>http://www.otbd.org/mount-sinai-invents-gene-signature-to-identify-individuals-with-cirrhosis-at-high-risk-for-liver-cancer/#comments</comments>
		<pubDate>Wed, 17 Apr 2013 14:18:49 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Blue Mountain]]></category>

		<guid isPermaLink="false">http://www.otbd.org/?p=2027</guid>
		<description><![CDATA[April 17, 2013 - Researchers at the Icahn School of Medicine at Mount Sinai have developed the first-ever gene test that could be used to identify patients with cirrhosis who are at highest risk of developing the most common type of liver cancer, hepatocelluar carcinoma (HCC). The test will also help determine whether a patient diagnosed [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/mount-sinai-invents-gene-signature-to-identify-individuals-with-cirrhosis-at-high-risk-for-liver-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Icahn School of Medicine at Mount Sinai Partners with Genisphere to Develop Rapid, High-Throughput Allergy Test</title>
		<link>http://www.otbd.org/the-icahn-school-of-medicine-at-mount-sinai-partners-with-genisphere-to-develop-rapid-high-throughput-allergy-test/</link>
		<comments>http://www.otbd.org/the-icahn-school-of-medicine-at-mount-sinai-partners-with-genisphere-to-develop-rapid-high-throughput-allergy-test/#comments</comments>
		<pubDate>Thu, 31 Jan 2013 16:48:10 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Blue Mountain]]></category>

		<guid isPermaLink="false">http://www.otbd.org/?p=1741</guid>
		<description><![CDATA[January 31, 2013 &#8211; The Icahn School of Medicine at Mount Sinai and Genisphere have agreed to jointly develop a new allergy test that will quickly and effectively characterize patients’ food allergies. The peptide-bead-based test will be high-throughput, semi-automatic and accurate, surpassing the reliability of current allergy-testing methods. The partnership was established through Mount Sinai’s [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/the-icahn-school-of-medicine-at-mount-sinai-partners-with-genisphere-to-develop-rapid-high-throughput-allergy-test/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Teri F. Willey</title>
		<link>http://www.otbd.org/teri-f-willey/</link>
		<comments>http://www.otbd.org/teri-f-willey/#comments</comments>
		<pubDate>Wed, 09 Jan 2013 16:55:15 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Team]]></category>

		<guid isPermaLink="false">http://www.otbd.org/?p=1568</guid>
		<description><![CDATA[fdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfgfdgdfghdsghdsgdfg]]></description>
		<wfw:commentRss>http://www.otbd.org/teri-f-willey/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Anti-Cancer Activity Drug IRX4204 Shows Promise as a Potential Disease-Modifying Agent for Alzheimer’s Disease</title>
		<link>http://www.otbd.org/anti-cancer-activity-drug-irx4204-shows-promise-as-a-potential-disease-modifying-agent-for-alzheimers-disease/</link>
		<comments>http://www.otbd.org/anti-cancer-activity-drug-irx4204-shows-promise-as-a-potential-disease-modifying-agent-for-alzheimers-disease/#comments</comments>
		<pubDate>Thu, 13 Sep 2012 19:00:28 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>

		<guid isPermaLink="false">http://mssm-technology.com/?p=1162</guid>
		<description><![CDATA[September 13, 2012 - New research presented today at the 6th Neurodegenerative Conditions Research and Development Conference in San Francisco, California demonstrates the role of the investigational compound IRX4204 in alleviating cognitive decline in animal models of Alzheimer&#8217;s disease. The presentation entitled &#8220;Investigation of the RXR-specific agonist IRX4204 as a Disease Modifying Agent of Alzheimer&#8217;s Disease [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/anti-cancer-activity-drug-irx4204-shows-promise-as-a-potential-disease-modifying-agent-for-alzheimers-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mount Sinai Researchers Develop New Computational Method to Find Novel Connections from Gene to Gene, Drug to Drug and Between Scientists</title>
		<link>http://www.otbd.org/mount-sinai-researchers-develop-new-computational-method-to-find-novel-connections-from-gene-to-gene-drug-to-drug-and-between-scientists/</link>
		<comments>http://www.otbd.org/mount-sinai-researchers-develop-new-computational-method-to-find-novel-connections-from-gene-to-gene-drug-to-drug-and-between-scientists/#comments</comments>
		<pubDate>Mon, 23 Jul 2012 13:08:27 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>

		<guid isPermaLink="false">http://mssm-technology.com/?p=801</guid>
		<description><![CDATA[July 23, 2012 &#8211; Researchers from Mount Sinai School of Medicine have developed a new computational method that will help organize scientific data, making it easier for scientists to identify and prioritize genes, drug targets, and connections between drugs. By mining large datasets more simply and efficiently, researchers will be able to better understand gene-gene, [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/mount-sinai-researchers-develop-new-computational-method-to-find-novel-connections-from-gene-to-gene-drug-to-drug-and-between-scientists/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mount Sinai School of Medicine and PATH Agree To Collaborate on Novel Influenza Vaccine Research</title>
		<link>http://www.otbd.org/mount-sinai-school-of-medicine-and-path-agree-to-collaborate-on-novel-influenza-vaccine-research/</link>
		<comments>http://www.otbd.org/mount-sinai-school-of-medicine-and-path-agree-to-collaborate-on-novel-influenza-vaccine-research/#comments</comments>
		<pubDate>Mon, 16 Jul 2012 19:55:26 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>

		<guid isPermaLink="false">http://mssm-technology.com/?p=593</guid>
		<description><![CDATA[July 16, 2012 - Mount Sinai School of Medicine (MSSM) and PATH have reached an agreement to partner on new vaccine research aimed at eliciting broadly-protective immunity against influenza viruses. The collaboration seeks to develop promising influenza vaccines that can be made available and affordable to people in lower-resource countries. The agreement calls for PATH to [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/mount-sinai-school-of-medicine-and-path-agree-to-collaborate-on-novel-influenza-vaccine-research/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mount Sinai Researchers Develop A Multi-Target Approach To Treating Tumors</title>
		<link>http://www.otbd.org/mount-sinai-researchers-develop-a-multi-target-approach-to-treating-tumors/</link>
		<comments>http://www.otbd.org/mount-sinai-researchers-develop-a-multi-target-approach-to-treating-tumors/#comments</comments>
		<pubDate>Thu, 07 Jun 2012 14:01:13 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>

		<guid isPermaLink="false">http://mssm-technology.com/?p=964</guid>
		<description><![CDATA[June 7, 2012 &#8211; Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound AD80 that precisely targets multiple cancer genes. Tested in mouse models, the drug [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/mount-sinai-researchers-develop-a-multi-target-approach-to-treating-tumors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Partnership Investment Fund Awards $1M to Support Four Promising Biomedical Products</title>
		<link>http://www.otbd.org/partnership-investment-fund-awards-1m-to-support-four-promising-biomedical-products/</link>
		<comments>http://www.otbd.org/partnership-investment-fund-awards-1m-to-support-four-promising-biomedical-products/#comments</comments>
		<pubDate>Mon, 04 Jun 2012 19:33:09 +0000</pubDate>
		<dc:creator>mcnulty.neil</dc:creator>
				<category><![CDATA[Announcements]]></category>

		<guid isPermaLink="false">http://mssm-technology.com/?p=274</guid>
		<description><![CDATA[June 4, 2012 &#8211; The Partnership for New York City (PFNYC) today announced that four local scientists have been awarded a total of $1 million to fund the final stages of research on new biomedical products that will be developed in the five boroughs.  This is the third round of an annual competition known as [...]]]></description>
		<wfw:commentRss>http://www.otbd.org/partnership-investment-fund-awards-1m-to-support-four-promising-biomedical-products/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
<!-- This Quick Cache file was built for (  www.otbd.org/feed/ ) in 3.68578 seconds, on May 25th, 2013 at 6:13 am UTC. -->
<!-- This Quick Cache file will automatically expire ( and be re-built automatically ) on May 25th, 2013 at 7:13 am UTC -->